Eli Lilly announced promising mid-stage trial results for EloraTZP, a new obesity drug that led to up to 23.3% weight loss in overweight or obese type 2 diabetes patients after 48 weeks, outperforming Novo Nordisk's tirzepatide alone. The drug also significantly reduced blood sugar levels but had higher treatment discontinuation due to side effects. Lilly plans phase III trials by the end of 2026 to improve tolerability and confirm results. This intensifies competition in the obesity drug market, potentially pressuring Novo Nordisk's next-generation treatments.
As of Oct 02, 2026 14:02 WIB, Novo Nordisk (NVO) trades at USD 37.41, near its 52-week low of USD 35.29 and far from its 52-week high of USD 63.98, showing limited price movement with a 1-day change of +0.03%. In contrast, Eli Lilly (LLY) stands at USD 1,151.37, closer to its 52-week high of USD 1.28K than its low of USD 799.57, with a flat 1-day change of -0.00%. Despite the competitive pressure from Eli Lilly's new obesity drug data, investor activity on Pluang shows more selling interest in Novo Nordisk (60% Sell) compared to a more balanced sentiment for Eli Lilly (52% Sell).
Novo's drug CagriSema has demonstrated a significant 25% weight loss effect in women, a promising result that could boost the company's prospects. This development is important as it may help revive investor confidence and improve the company's stock...
OpenAI has acquired Orchestra Bio, a four-year-old AI biotech startup that develops software to assist biotech firms in managing drug discovery tasks such as finances and clinical trial scheduling. The acquisition aims to integrate Orchestra's techno...
Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight managemen...
Novo Nordisk's experimental obesity drug CagriSema demonstrated an average 25% weight loss among adult women after 68 weeks in a new analysis following a late-stage trial. The drug, combining semaglutide and cagrilintide, also showed significant weig...
Eli Lilly reported strong Q2 earnings with revenue up 47.67% and EPS beating estimates, driven by high sales of its obesity drug Mounjaro. The company raised its 2026 revenue guidance to $85-$87 billion and is optimistic about the upcoming U.S. filin...
